

**Virginia's Department of Medical Assistance Services
Pharmacy and Therapeutics Committee Meeting**

*600 East Broad Street – 7th Floor Conference Rooms
Richmond, Virginia 23219*

Wednesday, September 26, 2018 - 10:00 a.m.

Welcome and Comments from DMAS' Director

Dr. Jennifer Lee

Comments from DMAS' Chief Medical Officer

Kate Neuhausen, MD, MPH

Call to Order

Dr. Neuhausen, Chairman

Approval of Minutes From April 19, 2018 Meeting

P&T Committee Members

Drug Utilization Review (DUR) Board Update

Rachel Cain, PharmD

P&T Committee By-laws

Dr. Neuhausen

PDL Management

P&T Committee Members

• **PDL Phase II – New Drug Review (Therapeutic Class)**

Brand Drugs

- Olumiant[®] (Cytokine And Cam Antagonists)
- TaperDex[®] (Glucocorticoids, Oral)
- Invexxy[®] (Vaginal Estrogen Preparations)
- RoxyBond[™] (Analgesics, Narcotics Short)

Generics Drugs or New Dosage Forms

- Buprenorphine-Naloxone Film (generic for Suboxone[®]), (Opiate Dependence Treatments) (*Closed Class*)
- Hydroxyprogesterone Caproate (generic for Makena SDV) (Progestational Agents)

• **PDL Phase I – Annual Review**

Antibiotic-Anti-Infective

- Antibiotics, Vaginal

Antivirals

- Hepatitis C Agents (*Closed Class*)

Blood Modifiers

- Bile Salts
- Phosphate Binders

Cardiac Medications

- Angiotensin Modulators (*ACEs, ARBs, & CCB combination products*)
- Angiotensin Modulators II (*Direct Renin Inhibitors & combination products*)
- Antihypertensives, Sympatholytics (*Closed Class*)
- Beta Blockers (*includes combination products*)
- Calcium Channel Blockers (*includes dihydropyridine and non-dihydropyridine agents*)
- Lipotropics, Other (*includes Bile Acid Sequestrants, Cholesterol Absorption Inhibitor agents, Fibrin Acid derivatives, Microsomal Triglyceride Transfer Protein Inhibitors, Niacin derivatives, Oligonucleotide Inhibitors and Omega 3 agents*)
- Lipotropics, Statins
- Pulmonary Arterial Hypertension Agents (*Endothelin-1 agents, PDE-5 Inhibitors; Prostacyclin analogues, Prostacyclin Vasodilators, Soluble Guanylate Cyclase Stimulators*)

Central Nervous System

- Alzheimer's Agents
- Anticonvulsants
- Antidepressants, Other
- Antidepressants, SSRI
- Antipsychotics (*includes oral and long-acting injectables*) (*Closed Class – LA injectables only*)
- Sedative Hypnotics (*includes other Hypnotics*)

Dermatologic Agents

- Immunological Atopic Dermatitis
- Steroids, Topical

Endocrine & Metabolic Agents

- Glucocorticoids, Oral
- Growth Hormones (*Closed Class*)
- Hereditary Angioedema (HAE)
- Progestins for Cachexia

Gastrointestinal

- Antiemetic/Antivertigo Agents
- Gastrointestinal (GI) Motility, Chronic
- Histamine-2 Receptor Antagonists (H-2RA)
- H. Pylori Treatment
- Proton Pump Inhibitors
- Ulcerative Colitis (*oral and rectal*)

Genitourinary

- BPH Agents (*includes Alpha Blockers, Androgen Hormone Inhibitors and Phosphodiesterase (PDE) 5 Inhibitors for BPH treatment*)
- Bladder Relaxants

Ophthalmics

- Allergic Conjunctivitis (*includes Ophthalmic Antihistamines & Mast Cell Stabilizers*)
- Antibiotics
- Antibiotic/Steroid Combinations
- Anti-Inflammatory Agents (*includes Ophthalmic NSAIDS & Corticosteroids*)
- Glaucoma Agents (*includes Alpha-2 Adrenergics, Beta-blockers, Carbonic Anhydrase Inhibitors, Prostaglandin Inhibitors*)

Respiratory

- Anti-Allergens, Oral
- Antibiotics, Inhaled (*Closed Class*)
- Antihistamines Minimally Sedating
- Bronchodilators, Long Acting Beta Adrenergics
- Bronchodilators, Short Acting Beta Adrenergics
- Cough & Cold Agents (*Legend*)
- COPD (*includes Anticholinergics, Bronchodilators and Phosphodiesterase 4 (PDE4) Inhibitors*) (*Closed Class*)
- Epinephrine, Self-Injected
- Glucocorticoids (*includes nebulized solutions, metered dose inhalers and combinations*) (*Closed Class*)
- Intranasal Rhinitis (*includes Antihistamines and Corticosteroids*)
- Leukotriene Modifiers

Confidential Meeting (Pricing Information Discussion)

**P&T Committee, DMAS & MMS Staff
Pursuant to 42 USC §1396r-8**

PDL Recommendations and Vote

P&T Committee Members

Criteria Discussion of Phase II New Drugs*

P&T Committee Members

Criteria Discussion of PDL Phase I Drug Classes*

P&T Committee Members

Next Meeting – **March 20, 2019**

Dr. Neuhausen, Chairman

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

Oral Presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on *only* the drug classes in Phase I which are scheduled for review at the September meeting and new drugs in PDL Phase II listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase I Annual Reviews – October 2017 to present
- New Drugs in PDL Phase I or II Drug Classes – October 2016 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than **2** minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send requested information to pdlinput@dmass.virginia.gov and dfmoody@magellanhealth.com by **5 p.m. EST on Wednesday, August 29, 2018.**

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmass.virginia.gov by **5 p.m. EST Wednesday, August 29, 2018.**

.